PubMed Health⌕ Search

Biomedical subjects

W Girke

Publications and source records attributed to W Girke.

32 records · Page 2Linked to original sources
PubMed1975

Effects of lithium on electromyographic recordings in man. Studies in manic-depressive patients and normal volunteers.

(1) EMG investigations in 17 female manic-depressive patients under long-term treatment with lithium salts showed a reduction of the maximal motor nerve conduction velocity (NCV) and of the duration of isolated potentials (IPs) in six cases. These changes, however, were not clearly due to the influence of lithium only. Psychopathology, additional medication, and other variables may have been also responsible for these finding. (2) NCV and IPs as well as the concentration of electrolytes in serum and RBC were determined in seven healthy volunteers before, during, and after lithium administration. NCV was significantly decreased and the duration of IPs slightly increased after 1 week of lithium intake. The magnesium serum concentration increased steadily during the experimental period. (3) Thus, the possibility cannot be excluded that symptoms of fatigue and muscular weakness in lithium-treated patients might be caused at least partially by changes of the peripheral nervous-muscular function.

Adult↗
PubMedDate not supplied

Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.

[123I]IBZM is a new radioactive labelled ligand which has a high affinity and specificity to D2-dopamine receptors. The in vivo kinetics of [123I]IBZM were studied in patients with unilateral and bilateral accentuated idiopathic Parkinson's disease. The uptake in the basal ganglias and the imaging properties of this D2 receptor antagonist as a radiopharmaceutical for SPECT examinations had to be investigated. 5 patients, aged 42-66 years, (2 m/3 f) were examined. Each patient received 185 MBq [123I]IBZM intravenously. Blood samples were taken 0-120 min post injection (p.i.) and time activity curves were plotted. Three SPECT examinations were performed (I: 30-50 min; II: 50-70 min; and III: 70-90 min p.i.). The count rates (counts/pixel) in the basal ganglias and the cerebellum were measured for each SPECT series on transverse slices using the region-of-interest technique. The time-activity curve of [123I]IBZM shows a rapid decline in plasma during the first 10 min followed by a plateau until 120 min after injection. The SPECT examinations demonstrate the highest count rate in the basal ganglia during SPECT series III (i.e., 70-90 min p.i.). The side-to-side difference of the count rates were in the range of 3% in four patients, and 10% in one patient. The biokinetic data of [123I]IBZM make this substance capable as a radiopharmaceutical for SPECT examinations. The basal ganglia are best visualized 70-90 min p.i., thus [123I]IBZM seems to be a promising imaging agent for diseases of the D2-dopaminergic receptor system.

Adult↗